GeoVax has less than one quarter of cash runway with no revenue and no disclosed financing plan. The company will need to raise capital imminently to fund operations through the planned H2 2026 Phase 3 trial. Expect a dilutive offering or reverse split announcement. The stock is a high-risk binary event play on GEO-MVA trial initiation and financing execution.
Price Chart
Executive Summary
GeoVax reported Q1 2026 net loss of $5.3M ($2.62/share) vs $5.4M ($11.20/share) in Q1 2025, with zero revenue after BARDA contract termination. Cash burn reduced cash to $1.3M from $3.1M at year-end 2025, providing less than one quarter of runway. The company continues to advance GEO-MVA toward a Phase 3 trial in H2 2026, but the cash position is critically low without a financing plan disclosed.
Key Financial Metrics
Key Facts
- Net loss of $5.3M for Q1 2026, essentially flat vs $5.4M in Q1 2025
- Zero revenue in Q1 2026 vs $1.6M in Q1 2025 after BARDA contract termination
- Cash balance fell to $1.3M at March 31, 2026 from $3.1M at December 31, 2025
- Stockholders' equity collapsed to $494K from $3.8M at year-end 2025
- Phase 3 GEO-MVA trial planned for H2 2026, but no financing to support it disclosed
- Weighted average shares outstanding surged to 2,008,134 from 478,192 YoY (320% dilution)
Financial Impact
Cash burn of ~$1.8M/month with only $1.3M remaining — less than one quarter of runway. Zero revenue stream. Dilution of 320% YoY in weighted average shares.
Risk Factors
- Cash runway of <1 quarter — imminent need for dilutive financing or bankruptcy risk
- Zero revenue stream after BARDA contract termination
- Stockholders' equity nearly wiped out at $494K vs $3.8M
- Phase 3 trial initiation in H2 2026 contingent on raising capital
- 320% YoY dilution in share count signals aggressive equity issuance
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-017070 |
| Document: govx20260513_8k.htm | 0001437749-26-017070 |
| Document: 0001437749-26-017070-index-headers.html | 0001437749-26-017070 |
| Document: 0001437749-26-017070-index.html | 0001437749-26-017070 |
| Document: 0001437749-26-017070.txt | 0001437749-26-017070 |
| 8-K Data (Synthetic) | 0001437749-26-017070 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 8-K | $0.2032 | awaiting T+60 | — | $0.2043 (−0.54%) |
Sep 24, 2026 4w ago | EFFECT | $0.3603 | awaiting T+60 | — | $0.2043 (+43.30%) |
Jun 4, 2026 20w ago | EFFECT | $1.79 $0.7210 | ▲ +59.72% | ▲ +61.60% | $0.2043 (+88.59%) |
May 26, 2026 22w ago | S-1 | $3.49 $0.5947 | ▼ −82.96% | ▼ −85.68% | $0.2043 (−94.15%) |
May 19, 2026 22w ago | 8-K | $2.23 $0.7180 | ▲ +67.80% | ▲ +72.81% | $0.2043 (+90.84%) |
May 14, 2026 23w ago | 8-K | $1.23 $0.7700 | ▲ +37.40% | ▲ +41.91% | $0.2043 (+83.39%) |
May 7, 2026 24w ago | 8-K | $1.67 $0.7620 | ▲ +54.37% | ▲ +59.21% | $0.2043 (+87.77%) |
Apr 22, 2026 26w ago | EFFECT | $1.17 $0.9742 | ▼ −16.73% | ▼ −21.51% | $0.2043 (−82.54%) |
Apr 20, 2026 27w ago | EFFECT | $1.17 $1.01 | ▲ +13.68% | ▲ +20.45% | $0.2043 (+82.54%) |
Apr 15, 2026 27w ago | 8-K | $1.23 $1.11 | ▲ +9.76% | ▲ +16.80% | $0.2043 (+83.39%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers